Welcome to our dedicated page for NewAmsterdam Pha news (Ticker: namsw), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pha stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NewAmsterdam Pha's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NewAmsterdam Pha's position in the market.
NewAmsterdam Pharma Company, a clinical-stage firm focused on cardiometabolic diseases, announced CEO Michael Davidson’s participation in the Cowen 43rd Annual Health Care Conference on March 7 and 8, 2023. Davidson will discuss cardiovascular therapies and present the company's innovations. NewAmsterdam is developing obicetrapib, an oral CETP inhibitor, aimed at reducing LDL-C levels in high-risk cardiovascular patients. Previous trials, including ROSE and ROSE2, showed significant LDL-C reductions with obicetrapib. The company recently completed a $328 million business combination with Frazier Lifesciences and secured licensing rights for obicetrapib in Europe.
NewAmsterdam Pharma Company announced that Michael Davidson, M.D., CEO, will present at the SVB Securities Global Biopharma Conference on February 16, 2023, at 1:00 p.m. ET. The presentation can be accessed live via the investor relations section of their website with an archived replay available later.
The company focuses on developing oral therapies for cardiometabolic diseases. Its lead candidate, obicetrapib, has shown promising Phase 2b trial results, achieving a median 51% reduction in LDL-C levels in high-risk cardiovascular patients. Recently, NewAmsterdam completed a business combination with Frazier Lifesciences, securing around $328 million in proceeds to further its development efforts.
NewAmsterdam Pharma announced the appointment of John W. Smither as an independent director on its Board of Directors, effective February 6, 2023. He will also serve as chair of the Audit Committee. Smither brings extensive experience in the life sciences sector, having previously held CFO roles at Arcutis Biotherapeutics and Sienna Biopharmaceuticals. His expertise is expected to support the company's ongoing clinical trials for obicetrapib and enhance its strategic leadership post-public listing. The company has a robust capital position, with approximately $328 million from its recent business combination and significant licensing agreements in Europe.
NewAmsterdam Pharma Company announced positive topline results from its Phase 2 clinical trial ROSE2, evaluating the LDL-C lowering effects of obicetrapib in combination with ezetimibe. The trial achieved its primary endpoint with a statistically significant median LDL-C reduction of 59% in the combination group compared to 6% in the placebo group (p < 0.0001). The combination was well-tolerated, and the company plans to advance to bioequivalence and Phase 3 trials. Obicetrapib is a promising CETP inhibitor aimed at improving treatment for patients needing additional LDL-C reduction alongside high-intensity statin therapy.
NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS) has appointed David Topper as Chief Financial Officer, effective January 1, 2023. Topper, who previously held leadership roles in capital markets, succeeds Louise Kooij, who becomes Chief Accounting Officer. The management team expressed confidence in Topper's expertise, particularly in navigating capital markets as NewAmsterdam advances obicetrapib, its key product for treating major cardiovascular diseases.
Founded in 2019, NewAmsterdam focuses on developing transformative therapies and has successfully completed a business combination in 2022.
NewAmsterdam Pharma Company N.V. completed its business combination with Frazier Lifesciences Acquisition Corporation on November 22, 2022. The transaction generated approximately $328 million in gross proceeds, including $235 million from an upsized private investment in public equity (PIPE). This financing is expected to extend the company's cash runway through 2026, covering pivotal Phase 3 trials for cardiovascular disease treatments. Trading under the new ticker symbols NAMS and NAMSW commenced on November 23, 2022.